MOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Evidence Level
Emerging
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Mitochondrial-derived peptide studied in AMPK signaling research.
/ 02
Mechanism of Action
Studied for AMPK activation, metabolic flexibility, and insulin sensitivity pathways.
/ 03
Research Applications
Cellular energy regulation and metabolic signaling.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Reported in preclinical models; human dosing not established.
/ 06
Potential Adverse Effects Reported in Research
Limited human safety data.
/ 07
Mechanism Deep Dive
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Research describes it as a metabolic signaling factor studied for AMPK pathway activation, regulation of folate-methionine cycle intermediates, and translocation to the nucleus in response to metabolic stress.
/ 08
Pathway Role
Operates as a mitochondria-to-nucleus signaling molecule within the cellular metabolic regulation pathway, sitting upstream of AMPK-dependent metabolic transcription programs.
/ 09
Biological Targets
/ 10
Research Applications
- Skeletal muscle metabolic homeostasis (preclinical)
- Insulin resistance models
- Exercise and metabolic adaptation research
- Age-related metabolic decline (animal models)
/ 11
Evidence Summary
Evidence is heavily preclinical, with strong mechanistic characterization in cell and animal studies. Human outcome data is limited.
Evidence Level Rationale
Rated emerging because mechanistic literature is robust but clinical translation has not been established at scale.
/ 12
Research Observation Timeline
Early Signal Window
Acute metabolic marker shifts in cell culture (hours)
Primary Study Window
Days to weeks in preclinical metabolic studies
Endpoint Type
Biomarker and metabolic signaling endpoints
Evidence Strength
Emerging preclinical
/ 13
Safety & Unknowns
Human safety data is sparse. Long-term effects, dose-response in humans, and population-level outcomes are not characterized.
/ 14
Research Limitations
No reliable human outcome timeline exists. Most data comes from rodent metabolic models with short experimental windows.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Emerging
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
SS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
BPC-157
Pentadecapeptide studied for tissue protection and repair models.
TB-500
Thymosin Beta-4 fragment
Synthetic fragment studied for cell migration and tissue remodeling.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.